Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

elephone replay will be available through November 6, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non- nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected timing and planned development activities for ANA598 and ANA773, including the trial design, occurrence, timing, and pace of future clinical trials, the timing for obtaining viral load data and expectations regarding such data, as well as the anticipated future clinical benefits of ANA598 and ANA773. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward- looking statements. For example, the results of preclinical studies and early clinical trials may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... including University of Oregon chemist Geraldine Richmond, have ... self-assembling, synthetic proteins called peptoid nanosheets that mimic ... -- detailed this week in a paper placed ... of the National Academy of Sciences -- ... the two-dimensional peptoid nanosheets that can be used ...
(Date:9/2/2014)... Myriant Corporation, a global renewable ... distribution agreement with Azelis Group, a specialty chemicals ... acid in the Nordics, Benelux, France, Iberia, Italy, ... the industrial and base chemicals markets. , “As ... far-reaching chemical portfolio with extensive distribution networks providing ...
(Date:9/2/2014)... 2, 2014  Synthetic Biologics, Inc. (NYSE MKT: ... drug candidates targeting specific pathogens that cause serious ... its final preclinical toxicology study of SYN-004. Per ... bridging study was required to move the Company,s ... the devastating effects of Clostridium difficile (C. ...
(Date:9/2/2014)... Melbourne, Victoria, Australia (PRWEB) September 02, 2014 ... may provide a cure for chronic tinnitus are seeking ... campaign, run on the Indiegogo platform ( http://igg.me/at/tinaway ), ... designed to be a therapeutic ‘mHealth’ app and is ... the brainchild of a team of biomedical and software ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... blood cells can clog arteries. Source: National Institutes of Health. ... , a gene therapy researcher, announced on Wednesday that it ... Research grant from the National Institutes of Health. , ,The ... for the treatment of anemia, a blood disorder that kills ...
... has been tested on lab mice with no apparent ... at a recent conference. Information supporting this conclusion was ... ,Strong was optimistic of the molecules ability to inhibit ... treatments, the companys proprietary EVade Ribonucleases are effective at ...
... up 31 percent for quarter ConjuGon CEO to ... Canadian cancer drug Wisconsin DOA buys Seritis software ... Web site GE Healthcare profits up ... 31 percent from the same quarter last year, the company has ...
Cached Biology Technology:Mirus receives $1.26 million SBIR grant to combat anemia 2Cancer treatment advances as trials show no harm to mice 2Tech Digest: whats moving in the Midwest 2Tech Digest: whats moving in the Midwest 3
(Date:9/2/2014)... rates between indigenous and non-indigenous women in Queensland, Australia, ... of stillbirth due to preventable causes, find researchers in ... BJOG: An International Journal of Obstetrics and Gynaecology ... from the Queensland Perinatal Data Collection and looked at ... to assess the differences in stillbirth rates over time ...
(Date:9/2/2014)... rupture through a U.S. suburb , Observations and ... in the hours and days after the August 24 ... the earthquake caused so much damage in the region, ... hosted by the American Geophysical Union. , ... Next Places to Direct Our Curiosity , Selecting ...
(Date:9/2/2014)... will present the prestigious Parker/Gentry Award to Mr. Rhett ... conservation awareness. The Parker/Gentry Award is given annually by ... organization whose efforts have had a significant impact on ... can serve as a model to others. , Rhett ... and conservation news website that draws more than 2 ...
Breaking Biology News(10 mins):Stillbirth gap closing between indigenous and non-indigenous women, shows Australian study 2Stillbirth gap closing between indigenous and non-indigenous women, shows Australian study 3This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2
... you ever met a cat that doesn't go crazy over ... the world don't respond to it at all, according to ... of Chemical & Engineering News, the weekly newsmagazine published by ... Catnip sensitivity is inherited, says Carolyn M. McDaniel, a veterinarian ...
... Florida researchers say they are a step closer to ... cancers before symptoms become apparent. , The findings, currently ... Sciences, involve introducing molecularly engineered strands of DNA into ... burst after they adhere to cancer proteins. , ...
... the gene responsible for controlling a first key step in ... in the journal Nature tomorrow (Thursday 27 October 2005). , ... take place once a sperm enters an egg, giving it ... reproducing animals. , The absence or mutation of this gene ...
Cached Biology News:Many cats unaffected by catnip, C&EN reports 2Scientists closer to new cancer detection method 2Scientists closer to new cancer detection method 3Scientists unpick genetics of first 15 minutes of life 2
The Cellject Elecroporator is suitable for all cell types including embryo, mammalian, plant, yeast and bacterial. Its has highly user-freindly programing and can be used remotely, for example in a l...
Request Info...
... Reverse Transcriptase (AMV RT) catalyzes the polymerization ... RNA:DNA hybrids (1). It requires a primer ... primers) as well as Mg2+ or Mn2+. ... activity. Both nonionic detergents and sulfhydryl compounds ...
Request Info...
Biology Products: